Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.

Journal of acquired immune deficiency syndromes (1999) - 1 Feb 2009

Spagnuolo Vincenzo, Gianotti Nicola, Seminari Elena, Galli Laura, Fusetti Giuliana, Salpietro Stefania, Lazzarin Adriano, Castagna Antonella

Abstract excerpt

OBJECTIVES: To evaluate changes in resistance to tipranavir/r (TPV/r) and darunavir/r (DRV/r) in patients who had failed a TPV/r-including regimen. METHODS: HIV genotypes obtained both at baseline and at tipranavir/r failure (TPVF) were analyzed in 47 HIV-infected patients failing a TPV/r-including regimen. Genotypes were evaluated through the Stanford mutation score: patients were ranked for TPV/r and DRV/r...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Reverse Transcriptase

Share to Pyridines

Share to Pyrones

Share to Sulfonamides

Share to Treatment Failure

Source

Identifiers

PMID: 19131889
DOI: 10.1097/QAI.0b013e31819367fc

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.PMID 19131889Read ↗

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.Semantic proximity Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.Semantic proximity Read ↗

Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.Semantic proximity Read ↗

Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.Semantic proximity Read ↗

[Resistance to darunavir].Semantic proximity Read ↗

HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures.Semantic proximity Read ↗

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).Semantic proximity Read ↗

Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.Semantic proximity Read ↗

Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.Semantic proximity Read ↗

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.Semantic proximity Read ↗

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.